HONG KONG, 26 January 2026 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology”, “Zhaoke” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company, is pleased to announce that the Company has expanded its partnership agreement with the leading manufacturer and distributor of healthcare products, AFT Pharmaceuticals Limited (“AFT”), for commercializing BRIMOCHOLTM PF (the “Product”) in Singapore. The Company has also established a strategic partnership with leading Asian ophthalmology company Senju Pharmaceutical Co., Ltd. (“Senju”) for the commercialization of the Product in Vietnam.
Zhaoke is granting AFT and Senju, exclusive distribution rights in Singapore and Vietnam respectively, which include the right to register, import, promote, distribute, market, and sell BRIMOCHOLTM PF in their corresponding markets. With these agreements, AFT and Senju become the 7th and 8th commercialization partners for BRIMOCHOL™ PF, underscoring our extensive commitment to global expansion.
BRIMOCHOLTM PF is a potential treatment to correct the loss of near vision associated with presbyopia, which is the Company’s core asset licensed from its partner Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. In June 2025, Tenpoint announced that the U.S. FDA accepted its New Drug Application (“NDA”). The FDA has set a Prescription Drug User Fee Act (“PDUFA”) date of 28 January 2026 for BRIMOCHOLTM PF.
Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented, “We are delighted to announce our partnerships with AFT in Singapore and with Senju in Vietnam for BRIMOCHOLTM PF, which marks an important milestone in building out our strategic Asian footprint for the drug. Through our collaborations with leading local distributors, BRIMOCHOLTM PF is now poised to be offered in South Korea, Australia, New Zealand, Thailand, Indonesia, the Taiwan region, Singapore and Vietnam. This coordinated regional approach reflects our long-term commitment to building strong commercial foundations and ensuring broad patient access. As we look ahead to regulatory approvals, we are excited about the opportunity to launch BRIMOCHOLTM PF across these markets.”
About BRIMOCHOLTM PF and BRIO-II Phase 3 Study
BRIMOCHOLTM PF is an investigational, preservative-free, once daily eyedrop to correct for the loss of near vision associated with aging. BRIO-II is a 3-arm, multicenter, randomized, double-masked, safety and efficacy study of BRIMOCHOLTM PF (carbachol/brimonidine tartrate fixed-dose combination) topical ophthalmic solution vs. carbachol monotherapy topical ophthalmic solution vs. a vehicle topical ophthalmic solution in subjects with emmetropic phakic or pseudophakic presbyopia (NCT05135286). The study enrolled 629 subjects across forty-seven sites in the United States.
About Presbyopia
Presbyopia is the gradual loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins in adults in their 40s[1] and becomes almost universal by age 50[2]. Presbyopia impacts billions of people globally[3] with approximately 600 million adults affected in China, South Korea and Southeast Asia[4]. In Australia, the total number of prevalence cases reached over 13.5 million in 2023, according to GlobalData[5]. Reading glasses are the most common solution for near-vision correction; however, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons. There are currently no approved presbyopia-correcting therapeutics in many countries across the Asia-Pacific region.
About AFT Pharmaceuticals Limited
AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. Its business model is to develop and in-license products for the markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license its products to local licensees and distributors to over 125 countries around the world. For more information about the company, please visit www.aftpharm.com.
About Senju Pharmaceutical Co., Ltd.
Senju is a privately held, research-based Japanese pharmaceutical company that develops, manufactures, and commercializes a variety of innovative products, focusing on the field of ophthalmology to improve the health and quality of vision for people worldwide. The characters that comprise Senju's company name in the Japanese language are "Sen" and "Ju", or "thousand" and "bringing happiness". Senju's mission is to improve the joy of living of people associated with the company through the development of original pharmaceutical products. Senju is headquartered in Osaka, Japan, and has its subsidiaries and representative offices around the world. More on www.senju.co.jp/english/.
About Tenpoint Therapeutics
Tenpoint Therapeutics Ltd. is a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating, investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. Tenpoint Therapeutics has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL™ PF, has filed the New Drug Application (NDA) and has received a Prescription Drug User Fee Act (PDUFA) date from the U.S. Food and Drug Administration (FDA) of Jan. 28, 2026. For more information, please visit: www.tenpointtherapeutics.com/
- End -
[1] World report on vision. (2019). Retrieved 29 April, 2022, from https://www.who.int/docs/default-source/documents/world-vision-report-post-launch-accessible.pdf?sfvrsn=1b29f0e7_2
[2] Polat, U., Schor, C., Tong, JL. et al. Training the brain to overcome the effect of aging on the human eye. Sci Rep 2, 278 (2012). https://doi.org/10.1038/srep00278
[3] Market Scope, Global Presbyopia-Correcting Surgery Market Report. April 2012.
[4] Tenpoint Therapeutics data on file
[5] GlobalData’s Epidemiology Market Size Search extracted on 18 December 2024.
